Iterion Therapeutics

Iterion is proud to continue sponsoring National Pediatric Cancer Foundation.

We are Initiating a Phase 1 clinical trial to investigate tegavivint in a first-line combination study with osimertinib in previously untreated patients with metastatic epidermal growth factor receptor (EGFR)-positive Non-Small Cell Lung Cancer (NSCLC).

Iterion Therapeutics Announces Initiation of Phase 1 Clinical Trial to Study Tegavivint in Combination with Osimertinib in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced the...

Initiation of Phase 1/2 Clinical Trial to Study Tegavivint in Pediatric Cancers

Iterion Therapeutics Announces Initiation of Phase 1/2 Clinical Trial to Study Tegavivint in Pediatric Cancers /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced the...

Great things happening as we continue our research.

Iterion Therapeutics Announces Initiation of Phase 1 Clinical Trial to Study Tegavivint in Acute Myeloid Leukemia /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced the...

Iterion is a proud sponsor of National Pediatric Cancer Foundation. We are excited to be part of this years Houston event - Fashion Funds the Cure! If you would like more information please see National Pediatric Cancer Foundation

Join us in our excitment as we welcome our new Chief Operating Officer, Jean Chang.

Iterion Therapeutics Hires Jean Chang as Chief Operating Officer /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced the...

Exciting times for us!

Iterion Therapeutics Confirms Safety of Tegavivint Following Completion of Enrollment in Phase 1/2a Expansion Study in Patients with Desmoid Tumors /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, announced today that...

Our very own Director of Translation Research
Ruolan Han, PhD

NUCLEAR β-CATENIN INHIBITOR - TBL1 - A Novel Target for Safe & Effective Blockade of the Nuclear β-catenin Signaling Pathway Ruolan Han, PhD, explains how targeting TBL1/TBLR1 enables specific silencing of oncogenic Wnt target gene expression without affecting other necessary cellular functions that are disrupted when targeting higher up the Wnt pathway.

We are excited to announce that we have entered into a strategic collaboration with Apollomics, the ideal partner to advance Tegavivint in the Greater China region.

https://www.globenewswire.com/news-release/2021/02/10/2173075/0/en/Apollomics-Inc-and-Iterion-Therapeutics-Announce-Exclusive-Collaboration-and-License-Agreement-to-Develop-and-Commercialize-Tegavivint-in-Greater-China.html

http://www.prnewswire.com/news-releases/iterion-therapeutics-initiates-enrollment-of-phase-2a-dose-expansion-study-of-tegavivint-in-patients-with-desmoid-tumors-301100338.html?tc=eml_cleartime

Iterion Therapeutics Initiates Enrollment of Phase 2a Dose Expansion Study of Tegavivint in Patients with Desmoid Tumors /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, announced today that...

https://www.businesswire.com/news/home/20181205005630/en/Iterion-Therapeutics-Initiates-Phase-Clinical-Study-Tegavivint

Iterion Therapeutics Initiates Phase I Clinical Study of Tegavivint in Patients with Desmoid Tumors Iterion Therapeutics, formerly known as Beta Cat Pharmaceuticals, today announced that it has initiated a multi-center Phase I clinical study of Tegav